To clear regulatory issues related to its purchase of Wright Medical, Stryker proposed DJO as a buyer for certain ankle and finger joint replacement lines.
The company's exposure in global markets caused revenue declines of -24% in 1H20, but MicroPort launched several new products to spur future growth
The company grew in the high single digits for 1H20 as it benefited from provincial procurement tenders and the acquisition of Libeier.
The company believes it outperformed peers and took at least half a point of share in the second calendar quarter on the strength of its technology.
The company announced the INnate Intramedullary Threaded Nail has treated 5,000 metacarpal fractures, reflecting rapid uptake of ExsoMed's technology.
The digital platform and application is designed to connect delivery of patient care with providers throughout the surgical and clinical episode.
The company launched the Osteo-Site Vertebral Balloon for vertebral augmentation, completing IZI's line of Vertebral Compression Fracture treatment options.
The company will use the capital to support ongoing clinical trials of its injectable Discogenic Cell Therapy (IDCT) for lumbar degenerative disc disease.
The company completed its first case in Canada of the lateral open wedge distal femoral osteotomy for the treatment of knee malalignment.
The company raises the funds through a non-brokered private placement. The proceeds will fund initiatives like securing FDA approval for clinical trials.